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Introduction
TLQP-21 is a neuropeptide expressed in the brain that is
involved in the control of energy homeostasis. In prelimin-
ary experiments we have observed that TLQP-21 can
modulate macrophage function. In Acute Respiratory
Distress Syndrome (ARDS) macrophage seems to play
a critical role, contributing to lung remodeling.
Objectives
To explore the therapeutic role of a short analog of
TLQP-21 (JMV5656) in an experimental model of ARDS.
Methods
C57/BL6 mice received an instillation of 0.1 M HCl, 2.5
ml/kg into the right bronchus. They were treated with
TLQP-21 0.6 mg/kg ip or vehicle control, 2 days before
and on the same day of HCl challenge. Respiratory system
compliance, blood gas analysis and differential cell counts
in a selective bronchoalveolar lavage (BAL) were deter-
mined 24 h after HCl. In a parallel experiment mice were
observed for 14 days to assess epithelial damage and lung
fibrosis.
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Figure 1 TLQP-21 module lung inflammation and fibrosis. A) Lower neutrophil count in the BALF of the right bronchus at 24 hours after
HCI. B) At day 14 lung compliance improved. C) Collagen deposition was lower in the mice treated with TLQP-21. * p ≤ 0.05.
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Results
The treatment with TLQP-21 showed a significant
decrease in the number of total cells in BALF, due to a
lower recruitment of neutrophils at 24 hour after challenge
with HCl, compared to the vehicle group (Figure 1A), with
no differences in macrophage number , even if this did not
translate in a functional improvement in lung compliance
and oxygenation. At day 14 the TLQP-21 group showed
an improvement in lung compliance (Figure 1B) and a
decrease collagen deposition in lung tissue (Figure 1C).
Conclusion
TLQP-21 can decrease inflammatory response at an
early phase in a mouse model of HCl-induced ARDS,
which may modulate lung remodeling at a late phase,
preventing a fibrotic evolution. Given these encouraging
but not definitive results we aim to furtherassess the
potential therapeutic effect of a higher dose of TLQP-21
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